Acute myeloid leukemia in the elderly: 'per aspera ad astra'? (Q33684133)

28 July 2017

1 reference

title

Acute myeloid leukemia in the elderly: 'per aspera ad astra'? (English)

1 reference

28 July 2017

1 reference

acute myeloid leukemia

1 reference

Latagliata R

1

1 reference

28 July 2017

Petti MC

series ordinal

2

1 reference

28 July 2017

Mandelli F

series ordinal

3

1 reference

28 July 2017

publication date

1 July 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

23

1 reference

28 July 2017

issue

7

1 reference

28 July 2017

page(s)

603-613

1 reference

Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Improved survival for patients with acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Acute myeloid leukemia in elderly adults.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Treatment of acute myeloid leukemia in the elderly: a clinical dilemma

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Treatment of acute myeloid leukemia in elderly patients. A retrospective study.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Age at death and rectangularisation of the survival curve: trends in Switzerland, 1969-1994.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Effects of aging on the renal glomerulus

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Treatment of acute nonlymphocytic leukemia in young and elderly patients.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Difference between young and old patients in characteristics of leukemic cells: older patients have cells growing excessively in vitro, with low antigenicity despite high HLA-DR antigens

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Impact of advanced age on the management of acute nonlymphocytic leukemia: a study of 103 patients

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

On the value of intensive remission-induction chemotherapy in elderly patients of 65 years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Acute myeloblastic leukemia in elderly patients: treatment and prognostic factors

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Validation of a model to predict survival in elderly patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

High-dose Ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Prognostic Factors in Elderly Patients with Acute Myeloid Leukaemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Differentiation of myeloid leukaemic cells: new possibilities for therapy

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years

1 reference

https://api.crossref.org/works/10.1016/S0145-2126(99)50085-5

7 January 2021

10.1016/S0145-2126(99)00085-5

Identifiers

DOI

1 reference

28 July 2017

1 reference